MASI Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of -58.2% compared to Masimo's net margin of -0.81%. Masimo's return on equity of -23.05% beat iRhythm Technologies's return on equity of -100.75%.

Masimo has a consensus price target of $195.70, signalling upside risk potential of 27.4%. On the other hand iRhythm Technologies has an analysts' consensus of $130.92 which suggests that it could grow by 26.86%. Given that Masimo has higher upside potential than iRhythm Technologies, analysts believe Masimo is more attractive than iRhythm Technologies.

Masimo has a beta of 1.278, which suggesting that the stock is 27.807% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.450, suggesting its more volatile than the S&P 500 by 44.979%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $600.7M, which are larger than iRhythm Technologies quarterly revenues of $164.3M. Masimo's net income of -$349.6M is lower than iRhythm Technologies's net income of -$1.3M. Notably, Masimo's price-to-earnings ratio is 116.80x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 3.97x versus 5.44x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of -58.2% compared to Masimo's net margin of 7.87%. Masimo's return on equity of -23.05% beat Merit Medical Systems's return on equity of 9.36%.

Masimo has a consensus price target of $195.70, signalling upside risk potential of 27.4%. On the other hand Merit Medical Systems has an analysts' consensus of $117.82 which suggests that it could grow by 26.35%. Given that Masimo has higher upside potential than Merit Medical Systems, analysts believe Masimo is more attractive than Merit Medical Systems.

Masimo has a beta of 1.278, which suggesting that the stock is 27.807% more volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.356%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $600.7M, which are larger than Merit Medical Systems quarterly revenues of $355.2M. Masimo's net income of -$349.6M is lower than Merit Medical Systems's net income of $27.9M. Notably, Masimo's price-to-earnings ratio is 116.80x while Merit Medical Systems's PE ratio is 45.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 3.97x versus 4.08x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -58.2% compared to Masimo's net margin of 16.85%. Masimo's return on equity of -23.05% beat Insulet's return on equity of 43.11%.

Masimo has a consensus price target of $195.70, signalling upside risk potential of 27.4%. On the other hand Insulet has an analysts' consensus of $312.92 which suggests that it could grow by 22.49%. Given that Masimo has higher upside potential than Insulet, analysts believe Masimo is more attractive than Insulet.

Masimo has a beta of 1.278, which suggesting that the stock is 27.807% more volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Masimo quarterly revenues are $600.7M, which are larger than Insulet quarterly revenues of $597.5M. Masimo's net income of -$349.6M is lower than Insulet's net income of $100.7M. Notably, Masimo's price-to-earnings ratio is 116.80x while Insulet's PE ratio is 44.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 3.97x versus 9.11x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -58.2% compared to Masimo's net margin of 26.88%. Masimo's return on equity of -23.05% beat ResMed's return on equity of 25.56%.

Masimo has a consensus price target of $195.70, signalling upside risk potential of 27.4%. On the other hand ResMed has an analysts' consensus of $267.15 which suggests that it could grow by 24.53%. Given that Masimo has higher upside potential than ResMed, analysts believe Masimo is more attractive than ResMed.

Masimo has a beta of 1.278, which suggesting that the stock is 27.807% more volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.97% to investors and pays a quarterly dividend of $0.53 per share. Masimo pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Masimo quarterly revenues are $600.7M, which are smaller than ResMed quarterly revenues of $1.3B. Masimo's net income of -$349.6M is lower than ResMed's net income of $344.6M. Notably, Masimo's price-to-earnings ratio is 116.80x while ResMed's PE ratio is 25.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 3.97x versus 6.42x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.